
|Videos|March 31, 2017 (Updated: November 11, 2020)
Novel Agents in Pancreatic Cancer
Author(s)Philip A. Philip, MD, PhD
This video covers the latest research in pancreatic cancer, including the possible role of PARP inhibitors, immunotherapy, and the novel drug PEGPH20.
Advertisement
In this video, Philip A. Philip, MD, PhD, of the Barbara Ann Karmanos Cancer Institute in Detroit, discusses the latest research developments and progress in the treatment of pancreatic cancer.
Philip touches on newer chemotherapy regimens such as FOLFIRINOX and gemcitabine plus nab-paclitaxel and highlights immunotherapy in this setting and targeted agents such as PARP inhibitors and a novel drug, pegylated recombinant human hyaluronidase (PEGPH20).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Accelerated Approval to Zongertinib in HER2+ NSCLC
2
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
3
How has Immunotherapy Evolved in Breast Cancer Treatment?
4
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
5













































